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As one of the most well-known inherited bleeding disorders, hemophilia A (HA) is 
caused by the deficiency or dysfunction of coagulation factor VIII (FVIII). Patients 
with HA (PWHA) suffer from abnormal bleeding after injuries or surgeries, or even 
spontaneous bleeding in severe cases, particularly at joints and muscles. The main 
treatment for PWHA is FVIII replacement therapy. Patients with the same residual 
FVIII levels may present different clinical bleeding phenotypes, thus individualized 
adjustment of the treatment is necessary. Moreover, the risks of cardiovascular 
disease (CVD) are increased in middle-aged or elderly patients. The management 
of CVD in PHWA has become a new clinical challenge. 
Circulating microparticles (MPs) are small membrane vesicles that originate mostly 
from platelets in healthy individuals. MPs play important roles in hemostasis and 
thrombosis and are reported to participate in the development of CVD. However, the 
role of MPs in hemostasis of HA as well as in the development of CVD in PWHA 
remains unclear. 
The overall aim of this thesis was to investigate the role of MPs in HA. The first part 
focused on the effect of MPs on hemostasis of HA in vitro and in vivo. In the second 
part, the prevalence of CVD, the profiles of MPs, as well as their correlations in the 
middle-aged and elderly PWHA were investigated. In another study, fibrin formation 
for combinations of a new bispecific antibody and bypassing agents (aPCC or rFVIIa) 
was studied using in vitro approaches.      
In Paper I, we characterized the fibrin formation and fibrin clot structure in a human 
plasma model of severe HA after the addition of sequence-identical analogue (SIA) of 
emicizumab, alone or in combinations with bypassing agents (aPCC or rFVIIa). The 
combination of SIA and aPCC exhibited hypercoagulable patterns, suggesting that 
this combination might introduce thrombotic risk when used to treat PWHA.  
In Papers II and IV, the procoagulant effect of MPs in HA was studied using in vitro 
plasma models and in vivo mouse models of HA, respectively. MPs improved 
hemostasis and were found to be incorporated into the fibrin network in both in vitro 
and in vivo HA models. 
In Paper III, the prevalence of subclinical CVD in a Swedish PWHA (≥40 years old) 
cohort was determined using the advanced electrocardiography (A-ECG) technique, 
retrospectively. PWHA were found to have higher probabilities of developing CVD 
 
 
compared to the age-matched male control. In Paper V, a cross-sectional study with 
a Chinese cohort of PWHA treated on-demand (≥30 years old) was conducted. PWHA 
treated on-demand were not protected from developing subclinical CVD. No 
correlations between the CVD risks and MPs profiles were observed. In addition, the 
hypercoagulable state might lead to increased platelet activation in PWHA. 
Taken together, this thesis has provided new insights to understand the procoagulant 
effect of MPs in HA and confirmed that PWHA are not protected from developing CVD. 
MPs may modify the clinical bleeding phenotypes in PWHA. Moreover, MPs might be 
a potential biomarker for individualized therapy in PWHA, particularly for aging 
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1.1 HEMOPHILIA A (HA) 
1.1.1 Introduction  
Hemophilia A (HA) is a recessive X-linked bleeding disorder characterized by 
deficiency or dysfunction of the coagulation factor VIII (FVIII)1. HA is caused by a 
mutation in the F8 gene, which affects 1 in 5000 male births2. Approximately 70% of 
patients with HA (PWHA) have a positive family history, while 30% are due to 
spontaneous mutations1. PWHA suffer from recurrent bleeding episodes in joints and 
muscles3. Lack of treatment leads to chronic arthropathy, limited movement of joints, 
and disability. Severe intracranial hemorrhages and bleedings in other organs can be 
life-threatening in PWHA1. 
 
HA should be suspected in males with an unexplained or excessive bleeding history. 
HA is diagnosed with blood tests including coagulation screening tests and FVIII 
activity tests. The coagulation screening tests typically show a normal prothrombin 
time (PT), but a prolonged activated partial thromboplastin time (aPTT)4. The residual 
FVIII activity in plasma can be measured using one-stage clotting or chromogenic 
assays5. PWHA are classified as three groups, according to predicted disease 
severity: severe (<1% of normal FVIII activity), moderate (1-5%), and mild (5-40%)6. 
The proportions of patients with severe, moderate, and mild HA are about 50%, 10%, 
and 40%, respectively. Patients with severe HA usually suffer from spontaneous 
bleeding or excessive bleeding even after a minor injury, while those with moderate or 
mild HA only bleed abnormally after trauma or surgery. 
 
1.1.2 HA and cell-based coagulation model 
There are two currently accepted coagulation models: 1) the classical coagulation 
cascade model; and 2) the cell-based coagulation model7. 
 
The classical coagulation cascade model is shown in Figure 1.1 and suggests that 
there are two independent coagulation pathways in normal individuals: the intrinsic 
(measured by the aPTT test) and the extrinsic (evaluated by the PT test) coagulation 
pathways. These two coagulation pathways merged into the common pathway which 
generates thrombin, which then leads to the formation of stable fibrin clots8. Although 
the classical coagulation cascade model supports the laboratory evaluations of HA 
 
2 
(prolonged aPTT and normal PT), it does not explain why the extrinsic pathway fails 
to compensate for the deficiency in the intrinsic pathway (deficiency of FVIII) in HA.   
 
 
Figure 1.1 Classical coagulation cascade model, including the intrinsic pathway (Red), the extrinsic 
pathway (Blue), and the common pathway (Green). Coagulation (both the intrinsic and common 
pathways) is impaired in PWHA due to the deficiency of FVIII. PWHA exhibit prolonged aPTT and 
normal PT.    
 
The cell-based coagulation model is shown in Figure 1.2 and provides a better 
interpretation of the clotting mechanism defect seen in PWHA7. According to the cell-
based model, coagulation occurs in three overlapping phases: a) initiation, b) 
amplification, and c) propagation7.   
 
a) Initiation When a blood vessel is injured, coagulation is immediately initiated and 
two important processes occur during this phase10: 1) coagulation FVII binds tightly to 
the surface of tissue factor (TF) bearing cells, forming FVIIa-TF complex, which 
activates both FX and FIX (Figure 1.2); and 2) platelet activation: platelets adhere to 
the injured site by binding to von Willebrand factor (vWF), which acts as a bridge to 
connect platelets and collagen outside of the vessel. Once bound to collagen, platelets 
are activated, thus surface receptors become modified and stored proteins, including 






Figure 1.2 Cell-based coagulation model, which consists of a series of three overlapping steps: a), 
initiation phase; b), amplification phase; c), propagation phase. The amplification and propagation 
phases are impaired in PWHA due to the deficiency of FVIII. Modified with permission9. 
 
b) Amplification The FXa and FVa formed during the initiation phase leads to the 
generation of a small amount of thrombin, which transfers the initial hemostatic signal 
from the TF+ cells to the surface of platelets. Although thrombin in plasma can be 
rapidly inhibited by antithrombin (half-life time about 1 min), thrombin that binds to 
platelet surface receptors (e.g. glycoprotein Ib and protease-activated receptor-1) is 
protected from inhibition and has multiple important functions during this amplification 
phase (Figure 1.2)10.  
 
The binding of thrombin to platelet surface receptors leads to platelet activation, as 
characterized by the rearrangement of membrane phospholipids, conformation 
alteration of platelet surface receptors (glycoprotein IIb/IIIa, which binds to fibrinogen), 
and the release of partially activated FV, fibrinogen, and other stored proteins10-13. 
Both the platelet-derived partially activated FV and the plasma-derived FV can be 
completely activated by thrombin10.  
 
FVIII circulates in the blood as a complex with vWF14. Since both vWF and thrombin 
bind to the same platelet receptor (glycoprotein Ib), the FVIII/vWF complex is rapidly 
bound to thrombin, and FVIII gets activated to form FVIIIa10. Thrombin also activates 
FXI (FXIa), which in turn converts FIX to FIXa. The amplification phase is relatively 
normal in PWHA, except that the FVIII activation is impaired due to the deficiency of 
FVIII in the blood (Figure 1.2).  
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At the end of the amplification stage, platelets have the appropriate phospholipids and 
surface receptors and are packed with activated coagulation factors/cofactors (FVa, 
FIXa, and FVIIIa) on their membrane surface. These changes enable coagulation to 
move to the next phase, propagation.  
 
c) Propagation The FIXa generated during the earlier stages binds to FVIIIa to form 
the FIXa/FVIIIa complex, which activates FX to FXa on the platelet surface10. 
Immediately, FXa combines with its cofactor FVa to form the FXa/FVa complex. This 
complex causes a burst of thrombin generation and stable fibrin clot formation10. 
Deficiency of FVIII in HA impairs the generation of FXa, so less FIXa/FVIIIa complex 
is formed, blocking propagation, resulting in reduced or absent thrombin generation, 
and impaired fibrin clot formation (Figure 1.2).  
 
1.1.3 Bleeding modifiers of HA 
Although the residual FVIII activity generally correlates well with bleeding phenotype, 
patients with similar FVIII activity may present heterogeneous clinical characteristics15. 
For example, 85-90% of patients whose FVIII activity <1% have indeed severe HA 
phenotype, and typically experience 15-35 spontaneous bleedings per year on 
average if not treated. However, the remaining 10-15% of patients whose FVIII activity 
<1% experience few bleeding episodes and consequently less arthropathy, even 
without treatment, thus are not severe HA clinical phenotype16. It is important for the 
physicians and patients to be able to predict which of these patients with low FVIII will 
have severe vs. mild HA clinical bleeding phenotype. Much research is being 
conducted to understand the coagulation pathway mechanisms that could be 
responsible for these different clinical observations in PWHA and several potential 
modifiers have been identified, as listed below.  
 
1) Type of F8 gene mutation. HA is a monogenetic disease, and over 2000 different 
F8 gene mutations have been identified1, which can have widely different effects on 
the structure, function, and activity of the mutant FVIII proteins. Null mutations 
(including inversions, large deletions, and nonsense mutations, which lead to 
nonfunctional FVIII or no FVIII synthesis) in F8 gene usually cause severe bleeding 
phenotype in PWHA. Santogostino et al. studied 72 patients with <1% FVIII activity 
and found that a non-null mutation is an independent predictor of a mild HA clinical 
phenotype17. Genetic testing of PWHA for their type of F8 gene mutation is becoming 
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routine and provides important prognostic information on their clinical bleeding 
phenotype as well as response to treatement1,18.   
 
2) Compensating mutations (inherited thrombophilia). Inherited thrombophilia is 
a condition with an increased tendency to form clots in the blood, and is usually caused 
by abnormal levels or functions of coagulation factors (e.g. prothrombin and FV) or 
natural anticoagulants (e.g. antithrombin, protein C, and protein S). The influence of 
thrombophilic mutations in PWHA on their HA clinical phenotypes has been addressed 
in several cohort studies. Patients with FV Leiden or prothrombin G20210A mutations 
had lower FVIII concentrate consumption and less frequent bleeding19,20, however, 
other studies did not reveal the protective effect of thrombophilia21. Many mild bleeders 
do not carry any thrombophilic mutations, indicating that other mechanisms must be 
responsible for the heterogeneous bleeding phenotype in severe PWHA. 
 
3) Fibrinolysis. A few studies have investigated the role of fibrinolysis on the 
heterogeneous bleeding phenotype of PWHA22,23. Grunewald et al. found that PWHA 
who were severely hemorrhagic had elevated tissue-type plasminogen activator (t-
PA) concentration and pro-thrombin-activatable fibrinolysis inhibitor activity, and 
reduced levels of plasminogen activator inhibitor 1 (PAI 1) activity and t-PA-PAI 1 
complex23.  
 
4) Platelets counts and coagulant activity. Platelets are another plausible bleeding 
modifier in PWHA24. In 1973, Walsh et al. reported that PWHA with <1% FVIII and the 
mild clinical bleeding phenotype exhibited a higher level of platelet coagulant activity 
than those with severe bleeding phenotype25. Siegemund et al. studied platelet-rich 
plasma from patients with <1% FVIII and found that thrombin generation increased 
with platelet count, suggesting that individual differences in platelet function may 
modify the clinical bleeding phenotype of PWHA26. Several other studies on platelet 
function in hemophilia were reported27. Van Bladel et al. measured P-selectin on 
platelets and the level of soluble platelet activation markers in plasma and reported 
that platelet activation was increased in severe PWHA compared to those with mild-
moderate HA28. In a subsequent study with a larger population of severe PWHA, 
however, the same group did not find any relevant differences in platelet activation or 
platelet reactivity to different agonists29. The discordance of the two studies could be 
due to differences in patient selection and the definition of bleeding phenotype. 
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Several other studies also reported conflicting results regarding the role of platelet 
activation in HA, which suggests that further and larger studies are needed to unravel 
the role of platelets in the clinical phenotypes of PWHA30. One direction of this 
research is the investigation of microparticles (MPs) released from platelets31,32. 
 
1.1.4 Global hemostasis assays for HA 
The deficiency of coagulation FVIII in HA results in impaired thrombin generation, 
leading to ineffective clot formation. Assessment of the residual FVIII activity is used 
to diagnose HA and to monitor patients’ response to treatment. However, this assay 
only evaluates the initiation of clotting and does not give the complete picture of 
hemostasis. The new generation of global hemostasis assays provide additional 
information about coagulation in HA, such as the calibrated automated thrombogram 
(CAT) and the overall hemostasis potential (OHP) assays33,34. 
 
CAT assay. As described in the cell-based model of coagulation, thrombin generation 
plays an essential role in hemostasis, and no coagulation pathways could bypass 
thrombin. The CAT assay is a simple and rapid method to monitor the dynamics of 
thrombin generation as developed by Hemker et al.34. Synthetic thrombin substrate 
coupled with a fluorophore (Z-Gly-Gly-Arg-7-amino-4methylcoumarin) is added to the 
mixture of coagulation trigger and plasma sample. The fluorescent signal is 
continuously measured by a thrombinoscope, which is proportional to the amount of 
thrombin that is generated during the reaction. The parameters of thrombin generation 
are calculated using the Thrombinoscope BV software, and the underlying mathematic 
methods used for data management are as described35. Figure 1.3 shows 
representative thrombin generation curves of severe HA plasma and normal control 
plasma, and the impaired thrombin generation in HA can be characterized by the 
following parameters: a prolonged lag time and time to peak thrombin generation, 
reduced peak thrombin, and reduced endogenous thrombin potential (ETP)36.  
 
Several studies have established the correlations between the parameters of the CAT 
assay and the clinical bleeding phenotype of PWHA17,37,38. Patients with severe 
bleeding phenotype were reported to have ETP<50% of normal, regardless of their 
residual FVIII activities38. In patients with severe HA after a standard FVIII infusion, 
the plasma FVIII levels correlated with the ETP and peak thrombin values at the 
studied time points within 72 hours39. In addition, the CAT assay is also useful for 
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assessing treatment responses to bypassing agents in patients with FVIII inhibitor, as 
well as for evaluating the effect of novel treatments, such as emicizumab, and the 
therapeutics targeting the natural anticoagulant system40-42. Two major limitations 
have hindered the clinical use of the CAT assay, including the lack of pre-analytical 
standardizations and the difficulty to define the normal reference ranges for the 
parameters42. Nevertheless, the CAT assay could provide important information on 
the overall coagulation function for the research of HA. 
Figure 1.3 Examples of thrombin generation curves of normal control plasma and severe HA plasma 
as tested by the CAT assay. Reproduced with permission36. 
 
OHP assay Bleeding in PWHA is not only due to impaired thrombin generation, but 
also due to defective fibrin clot formation and premature fibrinolysis. To assess the 
fibrin formation and fibrinolysis, our lab developed a simple and high-throughput 
laboratory method, the OHP assay43. This assay is based on the continuous 
measurement of the absorbance values after adding coagulation trigger (small amount 
of thrombin and phospholipids) and calcium, with or without t-PA, to plasma. Each 
absorbance value corresponds to the amount of fibrin in the mixture at the particular 
time point, and the area under the curve of absorbance vs. time reflects the total fibrin 
formed throughout the monitored time period. Overall coagulation potential (OCP) was 
calculated as the area under the curve of fibrin formation, while the OHP was the area 
under the curve of fibrin formation and fibrinolysis, and the overall fibrinolytic potential 
(OFP) as OFP=([OCP-OHP]/OCP) x 100%. 
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Patients with severe HA may have various overall hemostasis profiles, and Figure 1.4 
shows typical OHP assay results, with an example of curves for the fibrin formation 
and fibrinolysis of three severe PWHA (all had FVIII levels <1%) as well as the normal 
control (NPP)33. We previously showed that the OHP values correlated with the 
residual FVIII levels in PWHA, moreover, the OHP values were significantly lower in 
the severe vs. the mild clinical bleeding phenotype groups of patients43. Furthermore, 




Figure 1.4 Example of fibrin formation-fibrinolysis curves of normal pooled plasma (NPP) and three 
different patients with severe HA (Patient 1, 2, and 3). Reproduced with permission33.  
 
1.1.5 Treatment of HA  
The current major treatment for HA is FVIII replacement therapy, either 
prophylactically or on-demand1. Patients with prophylaxis are treated with FVIII 
concentrates regularly, thus preventing spontaneous bleeding and chronic 
arthropathy. Patients with on-demand therapy are infused with FVIII concentrates only 
when a bleeding episode occurs or prior to invasive procedures. In general, patients 
with severe HA and some patients with moderate HA require regular prophylaxis to 
prevent severe debilitating arthropathy45. However, treatment of HA is unaffordable 
for most patients in many countries, and >75% of the patients worldwide are not 
regularly, if at all, treated46. 
 
FVIII concentrate was first purified from human blood in 1964 and has been used to 
treat PWHA ever since47. This treatment unfortunately led to the epidemics caused by 
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transfusion-related viral infections, such as human immunodeficiency virus and 
hepatitis B and C viruses, in PWHA in the late 1970s to 1980s. The epidemics were 
controlled by blood-borne virus inactivation and strict donor selection48. The 
introduction of recombinant FVIII in 1989 provided a safer and more convenient drug 
for both prophylaxis and on-demand treatment of PWHA49.  
 
The biggest challenge for the treatment with FVIII concentrate is the development of 
FVIII inhibitors. About 30% of patients with severe HA develop inhibitors during FVIII 
replacement therapy, mostly during the first 30 exposure days1. The most effective 
therapies for patients with FVIII inhibitors are the bypassing agents, which could 
restore thrombin generation independent of FVIII. There are two bypassing agents 
available, activated prothrombin complex concentrate (aPCC; also known as FEIBA) 
and recombinant activated factor VII (rFVIIa; also known as NovoSeven), however, 
bypassing agents are not always effective50. A novel bispecific antibody, emicizumab, 
offers an alternative approach for patients with or without inhibitors40. 
 
Other novel therapeutic approaches for HA have also been available. Novel FVIII 
concentrates with extended half-lives are being developed which could decrease the 
frequency of infusions51. In addition, non-factor products that targeted natural 
anticoagulants, such as TF pathway inhibitor and antithrombin, have also shown 
promising results in clinical studies45,52. Gene therapy is a promising method to clinical 
cure HA in the near future53. In particular, 6 of 7 PWHA treated with an adeno-
associated virus 5 vector carrying the normal F8 gene with a deleted B-domain, 
achieved sustained normal FVIII activity and level over a one-year period54.  
 
1.1.6 Cardiovascular disease (CVD) in patients with HA (PWHA)  
With improved treatment, especially the early initiation of prophylaxis, PWHA can now 
expect a normal lifespan55. According to the latest annual global survey of the World 
Federation of Hemophilia, 19% and 31% of PWHA are over 45 years old in the 
Americas and Europe, respectively56. Since the risk of developing cardiovascular 
disease (CVD) increases with age, middle-aged or elderly PWHA are considered to 
have higher risk for CVD events57. 
 
CVD risk factors of PWHA. The CVD risk factors are common among PWHA. In a 
cohort of 709 patients with hemophilia (≥30 years, including HA and hemophilia B, 
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HB), although the prevalence of obesity and hypercholesterolemia were lower among 
patients compared to the general age-matched male population, those of diabetes and 
smoking were similar58. Moreover, hypertension was more common among patients 
than in the general population59,60, for unclear reasons. One plausible explanation is 
the impaired renal function in patients due to renal bleeding or virus infection61. 
Additional reasons could be: 1) increased diagnosis in PWHA vs. normal individuals, 
as hypertension is more easily diagnosed in PWHA during their regular follow-up 
visits; and 2) the lack of physical activity among patients because of hemarthrosis or 
being discouraged due to bleeding risk.  
 
Atherosclerosis in PWHA. PWHA are not protected from developing 
atherosclerosis62. Sramek et al. reported that the carotid or femoral artery intima-
media thickness (IMT) were similar between patients with hemophilia and healthy 
controls63. Several studies also confirmed that the IMTs of PWHA and controls did not 
differ64-66. Tuinenburg et al. reported that coronary artery calcium score was slightly 
higher in PWHA compared with controls evaluated by computerized tomography 
(CT)62.  
 
CVD mortality in PWHA. Several cohort studies reported that PWHA have decreased 
mortality from CVD than the general population67,68. One potential explanation is that 
PWHA suffer from less atherosclerotic plaque rupture or their plaque ruptures are 
“silent”, which do not lead to atherothrombosis or arterial occlusion69. The 
cardiovascular mortality in PWHA was also suggested to be comparable to (instead 
of higher than) that of the general controls57. Nevertheless, there is growing evidence 




1.2 MICROPARTICLES (MPS)  
1.2.1 Introduction 
MPs, also called microvesicles or ectosomes, are small membrane vesicles (0.1-1 µm 
in diameter) originating from various types of cells70. MPs are released from the cell 
membranes upon cell activation or apoptosis71. The bilayer membrane structure of 
MPs resembles that of their parental cells, consisting of lipids and cell-specific surface 
protein markers. The internal components of MPs are consist of proteins, DNA, 
mRNA, and other cytoplasmic components derived from their parental cells71.  
 
One of the earliest studies of MPs was conducted by Chargaff and West in 1946, 
where they found that platelet-derived particles in normal plasma were procoagulant72. 
In 1967, Wolf named these “platelet dust”73. In the past decades, growing evidence 
has shown that MPs have heterogeneous cell origins, and exhibit diverse biological 
functions in different processes (e.g. coagulation, inflammation, immune response, 
tissue repair)70,71.  
 
The release of extracellular vesicles (EVs) by cells is an evolutionally conserved 
process for intercellular communication, which exists in both lower organisms like 
bacteria and parasites, and higher organisms as humans70. Apart from MPs, there are 
two other major subgroups of EVs, apoptotic bodies, and exosomes (Figure 1.5)70. 
Apoptotic bodies are released by cells upon apoptosis and are usually rapidly 
recognized and cleared by macrophages74. Apoptotic bodies have a larger size (1-5 
µm in diameter) compared to MPs and exosomes. Exosomes (30-100 in diameter) are 
derived from multivesicular bodies, which can fuse with the cell membrane to release 
the exosomes inside70. Apoptotic bodies and exosomes are not studied in this thesis, 
since we focused on the role of MPs.  
 
Circulating MPs in the blood-steam are derived from the blood cells, including 
platelets, lymphocytes, monocytes, and so on, as well as from the endothelial cells70. 
In healthy individuals, the majority of circulating MPs originate from platelets (PMPs) 
which represents usually 70%-80% of total blood MPs75,76, although a much lower 
percentage of PMPs was also reported77. In several pathological conditions, the levels 
of total and specific subtypes of MPs, as well as the protein and RNA content, were 
found to be altered70. The potential use of MPs as biomarkers for clinical diagnosis 




Figure 1.5 The release of MPs (also called microvesicles), exosomes, and apoptotic bodies by cells. 
Modified with permission70. 
 
1.2.2 Generation of MPs  
Although the detailed mechanisms of MP biogenesis have only started to be 
understood, rearrangement of cell membrane phospholipids asymmetry and 
cytoskeletal remodeling are essential in this process (Figure 1.6). Three Ca2+-
dependent enzymes, scramblase, flippase, and floppase, regulate the cell membrane 
phospholipids asymmetry78. Rearrangement of the phospholipid asymmetry 
(externalization of phosphatidylserine, PS) causes membrane curvature, which is 
important for MP formation71. Calpain, a Ca2+-dependent protease that can cleave 
cytoskeletal proteins, is involved in MP formation79. Similarly, caspase 2 and 
transglutaminase 2, which can regulate cytoskeletal dynamics, have also been 
suggested to participate in MP formation80,81. Additionally, lipid-rich microdomains are 
enriched in MPs and are associated with enhanced MP formation82.  
 
The generation and release of MPs can be viewed as a receptor-mediated event. 
When the coagulation mediators, such as collagen and thrombin, bind to their 
corresponding surface receptor(s) of platelets, the production of MPs is stimulated84. 
Other in vivo or in vitro stimuli for PMPs formation have also been reported, including 
lipopolysaccharide (LPS), tumor necrosis factor-α (TNF-α), interleukin-6, thrombin-
receptor-activating peptide, calcium ionophore A2318771. Similarly, LPS and TNF-α 
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could also promote MPs generation in monocytes, lymphocytes, and endothelial 
cells71.  
 
Figure 1.6 Possible mechanisms involved in the biogenesis of MPs. Reproduced with permission 83. 
 
1.2.3 Clearance of MPs 
The clearance of MPs in vivo remains unclear. Most studies were performed by 
infusing external MPs into animal models and then detecting the levels of the infused-
MPs in circulation. The reported half-lives of MPs in the circulation differ widely. Rank 
et al. monitored the MPs levels in patients after platelet transfusion and found that the 
half-lives of MPs were approx. 5 hours85. However, a much shorter half-life time has 
been reported in animal studies86-88. For example, the infused MPs were cleared from 
the blood of rabbits in less than 10 min88. Interestingly, the infused MPs that were 
incorporated into the thrombus in mice were found to remain for a longer period 
compared to those that were not incorporated into the thrombus86.  
 
Phagocytosis of MPs by the endothelial cells is considered as the primary mechanism 
for the elimination of MPs in vivo71. This phagocytosis is mediated by the PS-exposure 
of MPs, which are recognized by the scavenger receptors on endothelial cells87. Del-
1 (developmental endothelial locus-1), a surface protein of endothelial cells, is 
essential for the clearance of MPs in vivo89. Macrophages were also found to 




1.2.4 Isolation and characterization of MPs 
Standardized isolation, identification, and quantification of MPs are essential for 
studying MPs91. Pre-analytical procedures including sample collection, handling, and 
storage are important sources of artifacts, which may affect the concentration, 
composition, and function of MPs. For example, platelet activation during sampling will 
lead to the release of MPs, and therefore should be avoid92. Similarly, plasma should 
be depleted of platelets before freezing, since a freeze-thaw cycle will induce residue 
platelets to release MPs and fragments92. The protocol used for the isolation of MPs 
may also affect their concentration, purity, and function. Several methods have been 
established to isolate MPs from blood, and the principle behind these different 
techniques are based on either their physical properties such as size and density, or 
particular surface ligands present on MPs92.  
 
Due to the small size of MPs, the detection and identification of MPs, especially the 
small MPs, remains a challenge. Transmission electron microscopy is the golden 
standard method for imaging MPs and can visualize the smallest MPs92. While this 
method can measure the size distribution of MPs, it cannot measure the concentration 
of MPs due to the sample preparation procedure. Flow cytometry, a widely available 
technique, has the highest throughput for characterizing the profiles of MPs in normal 
individuals and patients with different diseases92. Using flow cytometry, MPs pass one 
by one through a laser beam, so that the light scattered (which is related to the size 
and density of MPs), as well as the emitted fluorescence signals (specific for specific 
markers), can be detected. 
 
1.2.5 Biological functions of MPs  
MPs have been proposed to play roles in coagulation, inflammation, and the 
development of cancer, etc70.  
 
Coagulation. The procoagulant properties of MPs depend on the exposure of PS on 
their surface. Some subtypes of MPs, such as leukocyte-derived MPs (LMPs) and 
endothelial-cell derived MPs (EMPs), also express TF and thus have a higher level of 
procoagulant activity93. PS is an anionic phospholipid, which is located in the inner 
layer of the cell membrane under resting conditions, and is flipped out upon activation 
or apoptosis94. The anionic PS on MPs is available to interact with positively charged 
coagulation factors, including factors VII, IX, X, and II31. The PS+ PMPs can be 
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considered a smaller version of activated platelets, which express receptors for 
collagen, vWF, as well as fibrinogen/fibrin (Figure 1.7)31.  
 
Figure 1.7 PMPs can be viewed as a smaller version of activated platelets. Reproduced with 
permission95. 
 
Inflammation. Increased levels of MPs have been found in patients with various 
inflammatory diseases71,96. MPs play a role in intercellular communication during 
inflammation. For example, the macrophage-derived MPs present in human 
atherosclerotic plaques were found to stimulate the proliferation of endothelial cells 
and to promote angiogenesis via CD40 ligation97. In another in vitro experiment, LMPs 
activated endothelial cells to release cytokines and express TF98.  
 
Cancer. Elevated levels of MPs, particularly TF+ MPs, have been reported in patients 
with several types of cancer99,100. Interestingly, TF+ MPs were shown to be associated 
with venous thrombosis in patients with pancreatic cancer101, but not in other types of 
cancer102. In a mouse thrombus formation model, the MPs derived from the Panc02 
pancreatic tumor cell line were injected into the mouse and those MPs were found to 
be accumulated in the developing thrombus86. PMPs can induce angiogenesis, and 




1.3 THE ROLE OF MPS IN HA 
1.3.1 MPs and hemostasis in HA 
MPs play an important role in hemostasis. Berckmans et al. found that MPs isolated 
from healthy individuals were mostly PMPs and they generate thrombin via a TF-
independent pathway76. Zubairova et al. compared fibrin clot formation and structure 
in normal plasma and MPs-depleted plasma and found that MPs in healthy individuals 
both accelerated thrombin generation and improve the structure and stability of fibrin 
clots by becoming incorporated into the fibrin network104.  
 
MPs are involved in several bleeding disorders. Patients with Castamans’s defect, a 
mild bleeding disorder, have prolonged bleeding time and a deficiency of PMPs 
generation105. This mild bleeding disorder suggests a potential contribution of PMPs 
on coagulation. Similarly, Scott syndrome, a rare congenital bleeding disorder, is 
characterized by reduced PS exposure on platelets and impaired MPs shedding106.  
 
Few studies have been published regarding MPs in HA. In one early study, Proulle et 
al. used a MP capture assay to study 79 hemophilic patients and 62 controls and found 
that the levels of MPs were similar in the two groups107. Recently, Jardim et al. 
compared the MPs profiles in 32 previously untreated PWHA and 47 healthy controls 
using flow cytometry and found that the level of several subtypes of MPs was elevated 
in the patient group108.  
 
MPs levels in PWHA are altered after treatment. Proulle et al. reported that the 
procoagulant activity of MPs increased after FVIIa infusion in 6 out of 15 patients109. 
Their study suggests that FVIIa could activate platelets to release PMPs, which could 
account for the hemostatic efficacy of FVIIa. Our previous study showed that MPs 
decreased in PWHA treated on-demand, which suggested that MPs were 
incorporated into the hemostatic plug formed at the injured site110.  
 
In a HA mice model, Hrachovinova et al. reported that an increased level of MPs, 
which was induced by soluble P-selectin, could normalize the tail vein bleeding time 
and shorten the aPTT time in HA mice111. These results suggest that procoagulant 
MPs could provide a novel potential therapeutic approach, however, the 
corresponding hemostatic effects of TF and PS upon MPs need to be further clarified. 
Kim et al. reported that MPs from aged red blood cells shortened tail bleeding time in 
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vivo and improved clot formation ex vivo in wild type (WT) mice112. Their data suggests 
that MPs may play an independent role to accelerate hemostasis, which could be 
beneficial for hemorrhaging patients. More detailed information is needed about how 
MPs contribute to hemostasis in HA. 
 
1.3.2 MPs and atherothrombosis in HA 
Research data suggest that MPs may play an important role in the development and 
manifestation of CVD113. Significant higher levels of circulating EMPs and PMPs were 
detected in patients with hypertension, diabetes mellitus, and metabolic syndrome 
compared to normal age-matched controls114-116. Elevation levels of MPs have also 
been observed in patients with atherosclerosis. An increased level of PMPs was 
correlated with the degree of atherosclerosis, as measured by the IMT of the carotid 
artery and the plaque burden117,118. An increased level of EMPs, which is associated 
with dysfunction of endothelial cells, has also been reported in various CVD119. 
 
Although PWHA were previously considered as being protected from CVD, there are 
increasing reports of atherothrombotic events among PWHA57-60,67-68. However, the 





The overall aim of this thesis was to investigate the effect of MPs on hemostasis of 
HA in vitro and in vivo; and to study the prevalence of CVD, the profiles of MPs, as 
well as their correlations in middle-aged and elderly PWHA.    
 
The specific aims for each study were: 
Paper I: 
I: To investigate the in vitro fibrin formation and fibrin clot structure for combinations of 
aPCC, rFVIIa, and a sequence-identical analogue of emicizumab (SIA) in a severe 
HA plasma model. 
 
Paper II and IV: 
II: To study the procoagulant effect of MPs in in vitro HA plasma models, and to confirm 
that MPs are incorporated into the fibrin network of HA plasma. 
IV: To evaluate the procoagulant effect of MPs in HA mouse, and to examine the 
incorporation of MPs into the thrombus formed at the injured site in vivo.  
 
Paper III and V: 
III: To determine the presence of subclinical CVD in asymptomatic PWHA using the 
advanced-electrocardiography (A-ECG) technique. 
V: To characterize the risks of CVD, the global hemostatic status, the MPs profiles, 




3 RESEARCH APPROACH 
The studies included in this thesis were designed to address specific research 
questions regarding MPs and their roles in HA. Three different approaches were used: 
in vitro assays, mouse model study approaches, and observational clinical study 
approaches. The methods used are described in this section, and further details can 
be found in the individual papers included in this thesis.    
 
3.1 METHODS FOR IN VITRO STUDIES (PAPERS I AND II) 
In vitro global hemostasis assays are increasingly used in coagulation research. Using 
the OHP assay and scanning electron microscopy (SEM) analysis, the potential 
hypercoagulability of co-administration of emicizumab and bypassing agents was 
investigated (in Paper I). Methods to study MPs are in the process of being developed 
and standardized. A combination of these methods and global hemostasis assays was 
used to study the procoagulant effect of MPs in in vitro HA plasma models (in Paper 
II), as described below.   
 
3.1.1 Isolation of MPs from PNP 
MPs were isolated from pooled normal human plasma (PNP). PNP-derived MPs were 
used in our studies because they exist under physiological conditions and thus are 
considered more natural, compared to the MPs derived from other sources (e.g. 
plasma of patients with different diseases, cultured cells). MPs were isolated from PNP 
via differential centrifugation, as described120. Platelets and other blood cells were 
removed from the blood sample by centrifugation twice at 3000 g for 15 min at 15°C. 
PNP was prepared by pooling the platelet-free plasma from the healthy individuals 
(n≥10 individuals for each batch of PNP) and the mixture was stored at −80°C in 1-2 
mL aliquots. To isolate MPs from PNP, PNP was thawed at 37°C for 4 min and 
centrifuged at 20,800 g for 30 min at 10°C. Subsequently, the pellet containing the 
MPs was washed with PBS buffer by centrifugation three times to remove any residual 
FVIII. MPs prepared for each experiment was characterized as described in Section 
3.1.2 below.  
 
3.1.2 Quantification of the isolated MPs 
The isolated MPs (as described in Section 3.1.1) were quantified using flow cytometry, 
which is a fast, convenient, and well-standardized method to characterize MPs120. The 
isolated MPs was incubated with lactadherin-FITC, and mouse anti-human antibodies 
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to two platelet surface markers, CD42a-PE and CD61-APC. After incubation, samples 
were tested using a FACs Canto I flow cytometer (BD). The size gate for MPs was 
defined by standard beads (Megamix Plus SSC beads)121. To discriminate between 
MPs and negative events (e.g. protein aggregates), a background control (triton X-
100 lysed MPs) was tested by flow cytometry122.  
 
Since there is no universal marker for total MPs and the majority (approx.80%) of MPs 
isolated from PNP are PMPs76, the number of PMPs was used to represent the 
concentration of the isolated MPs used in the in vitro coagulation tests. The 
concentration of PMPs in the isolated MPs sample was calculated as follows: 
Concentration (/μL) = (Events reading×4*550)/(44×20), and typically ranged from 0.9-
6.5 × 105/μL: 4 is the dilution of isolated MPs sample, 550 is the total volume of sample 
in the tube analyzed, 44 is the volume of the analyzed sample, and 20 is the volume 
of the diluted isolated MPs sample added in the tube. The concentrations of isolated 
MPs added to plasma in the in vitro coagulation tests were presented as “amount of 
PMPs/µL plasma” as described in Paper II. 
 
3.1.3 Calibrated automated thrombogram (CAT) assay 
The CAT assay is a global hemostasis assay, which measures the rate and the 
amount of thrombin generated in the plasma34. This method was used to study the 
effect of MPs at different concentrations (2, 3, and 7×104 PMPs/µL plasma) on 
thrombin generation in in vitro human HA plasma models, in the presence or absence 
of coagulation trigger. PPP-Reagent LOW was used as the coagulation trigger since 
it contains a low concentration of TF (1 pM) and it demonstrates high sensitivity to 
FVIII-deficiency. Coagulation was initiated by spiking calcium and fluorescent 
substrate to the plasma sample. The parameters including lag-time, peak thrombin 
generation, and ETP were determined using the thrombinoscope software34.  
 
3.1.4 Overall hemostasis potential (OHP) assay  
The OHP assay is another global hemostasis assay, which was used in the in vitro 
studies (Papers I and II) as well as in the mouse study (Paper IV) and observational 
clinical study (Paper V). It evaluates the overall fibrin formation and fibrinolysis in 
plasma33. Coagulation was initiated in the OHP assay by adding a small amount of 
exogenous thrombin (0.04 U/mL), phospholipids, and calcium to plasma, with or 
without exogenous t-PA (300 ng/mL). In Paper II, this method was used to study the 
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effect of MPs at different concentrations (2, 3, and 7×104 PMPs/µL plasma) on fibrin 
formation and fibrinolysis in in vitro human HA plasma models. The change of 
absorbance was monitored by a spectrophotometer. The fibrin aggregation curve (i.e. 
absorbance vs. time) represents the process of fibrin formation and polymerization, 
which is driven by the thrombin generated. The fibrinolysis curve represents the 
digestion of fibrin by plasmin, which is produced from plasminogen by tPA. The area 
under the curve and the turbidity parameters were calculated as described in the 
individual papers. As indicated in the papers, the fibrin gels produced in the OHP 
assay were further analyzed by SEM (see Section 3.1.5) to characterize the fibrin 
structure in more detail.   
 
3.1.5 Scanning electron microscopy (SEM) 
To study the fibrin network density and fibrin fiber thickness, the gels collected from 
the OHP assay were analyzed by SEM. The gels were washed with PBS, fixed with 
2.5% glutaraldehyde, and prepared for SEM imaging as described in Paper I. SEM 
images were acquired using an emission scanning electron microscope (Zeiss, 
Germany), and analyzed with Fiji software. 
 
3.1.6 Confocal microscopy 
Fibrin gels were formed on the coverslips by 20 µL mixture as described in the OHP 
assay (Section 3.1.4), with the addition of Alexa Fluor 594-fibrinogen. To visualize the 
structure of the fibrin gel in different sections, a Leica SP8 laser scanning confocal 
microscope with a 63x/1.4 oil lens (Leica Microsystems) was used. In each sample, z-
stacks were collected at 8 randomly chosen areas with 5 at the periphery and 3 in the 
center. Z-stacks, consisting of multiple layers taken at 0.3-μm intervals, were acquired, 
and the fibrin clot density was analyzed using Fiji software. 
 
3.1.7 Stimulated emission depletion (STED) microscopy  
Since the diameters of the majority of MPs and fibrin fibers were below the resolution 
limit of standard confocal microscopy (200-300 nm), we used stimulated emission 
depletion (STED) microscopy, which has a lateral resolution of 70 nm, to better resolve 
the location of MPs in the fibrin network. Fibrin gels prepared in Section 3.1.6 were 
incubated with Abberior STAR-635-conjugated anti-CD61 antibodies. Fibrin fibers 
containing Alexa Fluor 594-fibrinogen were visualized in the orange channel, while 
MPs were detected in the red channel. Images were acquired using an Abberior 
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Instruments setup (Abberior Instruments, Germany) with a Leica 100x, NA 1.4 




3.2 METHODS FOR MOUSE STUDIES (PAPER IV) 
Hemostasis is the process that stops bleeding at an injured blood vessel, which 
depends on the interactions of coagulation factors, platelets, blood vessels, and blood 
flow rate. Only the first two components can be measured in in vitro laboratory tests. 
To take into consideration the other coagulation components, it is necessary to 
perform in vivo studies, which enables us to investigate the effect of MPs in living 
conditions. Mice have similar coagulation factors and function as human beings. HA 
mouse models (having <1% FVIII activity) have been available since the 1990s and 
are important tools employed in the development of therapeutics for HA123.  
 
3.2.1 Saphenous vein bleeding model 
The saphenous vein bleeding model has been used to evaluate the effect of pro-
coagulant compounds in HA mouse in recent years124. The saphenous vein has 
relatively low blood pressure, and the injury in this model is inflicted at a specific 
anatomical site of the vein. This model has low variations and high sensitivity to 
evaluate procoagulant compounds compared to other bleeding models (e.g. tail 
bleeding model)124. Mice were administered with different drugs, and the saphenous 
vein bleeding model experiments were performed as described with minor 
modifications (Figure 3.1)124,125. After the primary bleeding stopped, we dislodged the 
primary clot to determine the secondary bleeding time125. This dislodging procedure 
was repeated each time after a new clot was formed at the injured site, over a 10-min 
period. The number of hemostasis events was recorded, and the bleeding time and 
blood loss were measured as described in Paper IV. Immediate after the bleeding 
model experiments, blood samples were taken from the mice.  
 
Figure 3.1 Timeline for the saphenous vein bleeding model. See Methods in Paper IV for details.  
 
3.2.2 Whole blood thrombin generation assay 
The whole blood thrombin generation assay requires only a small volume of the blood 
sample, which is ideal for murine studies126. Moreover, this assay is more 
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physiologically relevant compared to the plasma-based CAT assay, since it reflects 
the influence of platelets and other blood cells on thrombin generation. Fluorescent 
thrombin substrate was added to mouse whole blood, and coagulation was initiated 
after the addition of TF (final concentration 1 pM) and calcium. Thrombin generation 
was measured by monitoring the fluorescent signals using a Fluoroskan Ascent 
microplate fluorometer with Fluoroskan Ascent software (Thermolabsystem). A 
dedicated programmed spreadsheet template allowed the following parameters to be 
calculated: the peak of TG, thrombin activity/ETP before the peak (ETPp), lag-time, 
time to peak (tt peak), and velocity127. 
 
3.2.3 Cremaster muscle thrombus formation model 
To visualize the incorporation of MPs into the thrombus at the site of blood vessel 
injury, thrombus formation was monitored using the HA mice cremaster muscle model 
by intravital microscopy. MPs were isolated from human PNP as described and kept 
at −80°C after the addition of 50 mM trehalose (to protect the membrane structure and 
activities of MPs from freezing)128. After exposure of the cremaster muscle, blood 
vessels were examined using transmitted light with an Apo LWD 25 x/1.10 NA 
objective and Eclipse FN1 intravital microscope (Nikon). After testing in some pilot 
experiments, we summarized the following principles to choose the optimal site to 
induce the injury and to visualize the thrombus formation in HA mouse. Firstly, venules 
are preferred over arterioles, because vasoconstriction in arterioles upon injury usually 
interferes with the observation of thrombus formation. Secondly, the proximal part of 
the major venule is desired, since the blood flow is sufficient in this area. We found 
that in the periphery venules with a low flow rate, even minor injuries could terminate 
the blood flow immediately, therefore, the dynamics of thrombus formation could not 
be monitored. Lastly, we found that the optimal site for our study was along the major 
venule of the cremaster muscle, where a branch venule merged into it. Since we 
needed to induce the injury manually under the stereomicroscope, and then put the 
mouse back under the objective of the intravital microscope, an anatomical “landmark” 
near the injured site of the blood vessel makes it much easier to fetch on the thrombus 
formation promptly.  
 
Calcein-AM labeled human PNP-derived MPs were injected into HA mouse 
intravenously. An injury was induced by placing a 5% FeCl3 soaked filter paper (1 x 1 
mm) above the selected site of the venule for 20 s. The mouse was placed under the 
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intravital microscope to check whether a thrombus was formed and the injury process 
was repeated until a thrombus could be visualized. Time-lapse images were acquired 
using the microscope with a multiband filter cube (DAPI/FITC/TRITC). The calcein 
AM-labeled MPs were imaged via the FITC-channel.  
 
3.2.4 Clearance of MPs by mouse organs 
To study whether the infused human PNP-derived MPs were cleared by the mouse 
organs via endocytosis, mouse lung, liver, and spleen were collected after the 
cremaster muscle experiments. The organ samples were incubated with collagenase, 
filtered with 40 µm-cell strainers. After lysing red blood cells, the single-cell 
suspensions were resuspended in PBS buffer and examined using a Canto I flow 
cytometer. Single cells were identified along the diagonal of the SSC-H by SSC-A 
graph, and dead cells (which showed positive staining with propidium iodide) were 
excluded from the analysis. The cells which had endocytosed the calcein-AM-labeled 




3.3 METHODS FOR CLINICAL STUDIES (PAPERS III AND V) 
To study the prevalence of CVD in adult PWHA, we conducted observation clinical 
studies. To investigate the presence of clinical and/or subclinical CVD, the A-ECG 
technique was used. A-ECG can be performed rapidly and inexpensively in clinical 
practice, moreover, it shows higher accuracy for particular disease conditions than 
conventional ECG129. 
 
3.3.1 Study design and subject population  
Paper III describes a pilot retrospective of Swedish PWHA who had a digital ECG file 
available at the Karolinska University Hospital, Stockholm, Sweden. Paper V 
describes a cross-sectional study of Chinese PWHA treated on-demand conducted at 
the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. 
 
Paper III study subjects The patients in this study were identified retrospectively by 
reviewing the medical journals of PWHA (regardless of the HA severity) followed up 
at the Coagulation Unit, Department of Hematology, Karolinska University Hospital 
from 2005 to 2018. We included patients ≥40 years and had at least one digital ECG 
file available. Patients who were diagnosed with CVD were excluded. A total of twenty-
nine PWHA were included in this study, as shown in Figure 3.2. Twenty-nine age-
matched male controls were also included in the study. Further details regarding this 
study population are given in the Methods of Paper III.  
 
 




Paper V study subjects The patients in this study were recruited and examined at 
the Center of Genetics and Prenatal Diagnosis, the First Affiliated Hospital of 
Zhengzhou University, China. Male patients ≥30 years of age, diagnosed with HA, 
irrespective of the severity, and treated with factor concentrates on-demand were 
included in the study. Age-matched male controls from the general public were 
recruited in the same clinic by placing a local advertisement. The age cut-off in this 
study is younger than that used in the retrospective study in Paper III, since we aimed 
to be able to include more patients. A total of forty-two patients and thirty-seven 
controls were included in this study. Further details regarding this study population are 
given in the Methods of Paper V.  
 
3.3.2 Collection of clinical data and ECG files 
In Paper III, clinical data were retrospectively extracted from digital medical records in 
TakeCare®. Standard 12-leads ECG files, which were recorded under clinical 
conditions were exported from the digital database (MUSE® Cardiology Information 
System).  
 
In Paper V, clinical data and ECG files of the participants were obtained during their 
visit to the clinic. Clinical information was obtained by interview, and a 5-min ECG was 
recorded for each participant by a trained medical doctor. 
 
3.3.3 Advanced-electrocardiography (A-ECG) analysis 
ECG or A-ECG files were analyzed using the semi-automatic A-ECG software 
CardioSoft® (NASA, Johnson Space Center, TX, USA). In both Paper III and V, 
conventional ECG parameters such as the QRT and T wave durations, axes, and 
voltages amplitudes, and A-ECG parameters including the derived vector 
cardiographic ECG parameters and QRS and T waveform complexity measures were 
obtained. In addition, in Paper V, parameters for the beat-to-beat variability of the R-
to-R and QT intervals were also used.   
 
Previously validated A-ECG scores to determine the probability of having CVD, left 
ventricular systolic dysfunction (LVSD), coronary artery disease/coronary 
microvascular disease (CAD/CMVD), and left ventricular hypertrophy/left ventricular 




3.3.4 Analysis of circulating MPs by flow cytometry  
Blood was collected from the participants and centrifuged twice at 3,000 g for 10 min 
to obtain platelet-free plasma. The plasma sample was incubated with Annexin-V-
FITC (PS+ MPs), mouse anti-human antibodies against CD61-PE (PMPs), CD62P-
APC (P-selectin+ MPs), CD51/61-FITC (EMPs), CD142-PE (TF+ MPs), or CD45-APC 
(LMPs) for the identification and measurement of different subtypes of MPs. The 
samples were tested using the BD Canto II flow cytometer and analyzed using the 




3.4 METHODS FOR STATISTICAL ANALYSIS 
The IBM SPSS statistics (version 25.0) and Graph Pad Prism software were used to 
carry out the statistical analysis. To compare continuous variables, the Student t-test 
(for normally distributed data) or the Man-Whitney test (if data is not normally 
distributed or the sample size is relatively small) was used for comparison of two 
groups, and the Kruskal-Wallis test for comparison of more than two groups. To 
compare categorical variables, the Pearson Chi-square test was used. Correlation 
analysis was performed using Spearman’s rank correlation test. Sample sizes were 
determined empirically, and no statistical tests were used to predetermine the sample 




3.5 ETHICAL CONSIDERATIONS 
The study in Paper I did not involve any human participation, or collection of personal 
data, or usage of research animals. Therefore, an ethical permit was not required. 
The study in Paper II was part of a larger study, which was approved by the regional 
ethics review board in Stockholm (Dnr 01–0003;2006/778–32, completed with 
2013/1045–32, 2015/275–32 and 2018/1480–32). 
The study in Paper III was approved by the regional ethics review board in Stockholm 
(Dnr: 2018/636-31/2). The studies were conducted following the Declaration of 
Helsinki. 
The study in Paper IV was approved by the local ethics committee for the animal 
experiment in Sweden (Dnr 5708-2018). The “KI-mallen” was used to assess animal 
welfare. Mice were sacrificed if the humane endpoint was observed.  
The study in Paper V was approved by the ethical committee of the First Affiliated 
Hospital of Zhengzhou University, Zhengzhou, China (2020-KY-041). The studies 
were conducted following the Declaration of Helsinki, and informed consent was 




4 RESULTS AND DISCUSSION  
This section focuses on the key findings generated by the research work that was 
conducted for this thesis, categorized by sub-studies.  
 
4.1 THE EFFECT OF COMBINATIONS OF APCC, RFVIIA, AND SIA ON FIBRIN 
FORMATION IN VITRO IN A HUMAN PLASMA MODEL OF SEVERE HA 
(PAPER I) 
This part of the thesis focuses on the standardization of the coagulation assays (the 
OHP assay and SEM analysis) using in vitro HA plasma models, which were then 
used in the following studies included in this thesis.  
 
FVIII replacement therapy causes the development of FVIII inhibitors in approximately 
30% of PWHA and interferes with treatment efficacy1. To treat patients with FVIII 
inhibitors, bypassing agents (aPCC and rFVIIa) are used, however, they are not 
always effective1,50. Emicizumab (trade name Hemlibra) is a novel therapy for PWHA 
and has recently been approved to treat patients with or without inhibitors40,131. This 
drug is a humanized bispecific antibody that mimics the function of FVIII to connect 
FIXa and FX, thus activating FX and restoring coagulation in HA40. A potential concern 
with emicizumab treatment for PWHA is that when additional bypassing agents are 
used to control breakthrough bleeding, thrombotic events were reported131. The 
HAVEN study observed thrombotic microangiopathy (3 cases) and thrombosis (2 
cases: cavernous sinus thrombosis or skin necrosis-superficial thrombosis) in patients 
treated with a high cumulative dose of aPCC for breakthrough bleeding during the 
prophylactic administration of emicizumab; no thrombotic events were reported with 
the co-administration of emicizumab and rFVIIa131. 
 
In Paper I, the effect of SIA (synthesized based on the amino acid sequence of 
emicizumab), alone and in combination with bypass agents (aPCC or rFVIIa) was 
studied. One previous study investigated the effects of these drugs and drug 
combinations using the thrombin generation assay and the whole blood based 
rotational thromboelastometry assay132. In this study, we used the OHP assay and 
SEM analysis to study fibrin formation and fibrin clot structure.  
 
The combination of SIA with aPCC gave a higher OHP value and clotting rate 
compared to SIA alone (Figure 4.1). Although the OHP value did not reach the normal 
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range, the fibrin clotting rate surpassed the normal range dramatically (Figure 4.1). 
The results suggested that the combination of SIA and aPCC may lead to a 
hypercoagulable state in HA. This would be highly undesirable in the clinic because it 
would be expected to increase the risk of thrombotic events33. Our results confirmed 
the results in the previous study, which found that the peak thrombin value of the 
combination of SIA and aPCC exceeded the reference range132. The mechanism of 
the synergistic effect of aPCC-SIA combination is likely that aPCC contains FIX and 
FIXa, which enables SIA to form the FX activation complex more rapidly132.  
 
The combination of SIA and rFVIIa only slightly increased the OHP value and fibrin 
clotting rate compared to SIA alone, and the values were all below the normal range 
(Figure 4.1). No obvious synergistic effect was observed with this drug combination. 
These results suggest that the combination of SIA and rFVIIa could improve 
hemostasis slightly without increasing the thrombotic risks in PWHA, which is 
consistent with another in vitro study132.   
  
Figure 4.1 The OHP value and the clotting rate in the severe HA plasma model after the addition of SIA 
(200 or 600 nM) in combination with aPCC or rFVII, at different concentrations. Normal range: reference 
range presented as a minimum and maximum value measured in PNP. Reproduced from Paper I with 
permission.  
 
In summary, results in this study support conclusions of the previous studies, that 
additional caution should be taken when combinations of emicizumab and bypassing 
agents are used to treat PWHA. Treatment with a combination of emicizumab and 
rFVIIa is likely a safer approach vs. treatment with emicizumab and aPCC to control 
breakthrough bleeding in PWHA treated with emicizumab, in order to reduce the risk 
of thrombotic events.  
 
We did not investigate the role of MPs in PWHA treated with emicizumab in this thesis, 
and this is of further interest. Procoagulant MPs might be a potential biomarker for 
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bleeding or thrombosis risks for patients treated with emicizumab. Potential future 
work: To study the levels of MPs in PWHA treated with emicizumab, and; to investigate 
if the addition of MPs could enhance the procoagulant effect of emicizumab in in vitro 
HA plasma models and/or in HA mouse model.   
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4.2 THE EFFECT OF MPS ON HEMOSTASIS IN HA IN VITRO AND IN VIVO 
(PAPERS II, AND IV) 
MPs play important roles in coagulation, however, their procoagulant effect in the 
bleeding disorder, HA, is not understood31,32. Our lab previously reported a study in 
PWHA treated on-demand, the levels of MPs decreased after administration of FVIII 
concentrates. The hypothesis that was generated from this study was that MPs are 
incorporated into the hemostatic plugs formed at the site of injury in PWHA110. In the 
following thesis project, the aim was to better understand the procoagulant effect of 
MPs in HA, using the in vitro human HA plasma models (Paper II) and the HA mouse 
model (Paper IV). 
 
4.2.1 MPs improve hemostasis in vitro in human plasma models of HA 
(Paper II) 
Previous work by Berckmans et al. indicates that circulating MPs in healthy individuals 
support thrombin generation via TF-independent pathways76. We hypothesized that 
PNP-derived MPs could improve thrombin generation and fibrin formation in in vitro 
HA plasma models.  
 
It was previously (in 2014 and earlier) observed in our lab that interesting particle-like 
structures (around 50-200 nm in diameter) attached to fibrin fibers using SEM imaging 
(revealed in the studies aimed to investigate the fibrin clot structure in plasma sample 
from normal controls or patients with, eg. hemophilia or systematic lupus 
erythematosus patients, personal communication). They hypothesized that these 
particles were some type of MPs. Interestingly, another research group (Zubairova et 
al.) in 2015 reported a similar observation of particles attached to fibrin fibers in vitro, 
in clots of normal plasma, and they confirmed that these were MPs of platelet origin 
(PMPs) using confocal microscopy104. We hypothesized that MPs are incorporated 
into the fibrin network of HA formed in vitro, thus improving hemostasis in vitro. 
 
MPs improve thrombin and fibrin formation in HA plasma models via PS 
exposure on their membrane surface  
MPs increased peak thrombin generation dose-dependently in CAT assay using the 
in vitro severe HA plasma model, both with and without the addition of PPP-Reagent 
LOW (Figure 4.2). MPs (2 x 104 MPs/µL plasma) also increased peak thrombin 
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generation in the moderate and mild HA plasma models as well as in PNP (Figure 
4.2).  
 
Figure 4.2 PNP-derived MPs improve thrombin generation in HA plasma models as well as in PNP. (a) 
Thrombin generation in the severe HA plasma model with different concentrations of MPs (MP-0, 2, 3 
and 7: 0, 2, 3 and 7 × 104 MPs/μL plasma), in the presence (solid lines) and absence (dashed lines) of 
PPP Reagent LOW (CAT reagent). The inset shows thrombin generation curves (with an adjusted y-
axis scale) in the absence of CAT reagent. (b) Peak thrombin value in the severe HA plasma model. (c) 
Peak thrombin value in the moderate HA (2.5% FVIII), mild HA (20% FVIII) plasma models, and in PNP 
(100% FVIII) with MPs (2 × 104 MPs/μL plasma) in the presence of CAT reagent. Data shown are mean 
± SEM values, n = 9 replicates. Reproduced from Paper II with permission. 
 
MPs increased the OHP value dose-dependently in the severe HA plasma model, in 
the absence of OHP reagent (which contains thrombin and phospholipids) (Figure 
4.3). The procoagulant effect of MPs was decreased dramatically after lysing the MPs 
(7 x 104 MPs/µL plasma) with 0.25% TritonX-100 (Figure 4.3), suggesting that the 
intact membrane surface of MPs is of crucial importance for the hemostatic response. 
MPs (2 x 104 MPs/µL plasma) increased the OHP value in all HA plasma models as 
well as in PNP, in the presence of OHP reagent (Figure 4.3).  
 
Figure 4.3 The effect of MPs on fibrin clot formation and clot stability in different HA plasma models. (a) 
OHP values in the severe HA plasma model with the addition of different concentrations of MPs (2, 3, 
and 7 × 104 MPs/μL plasma) in the absence of OHP reagent. Lysed MPs: MPs (7 × 104 MPs/μL plasma) 
were treated with TritonX-100; (b) OHP values in different HA plasma models and PNP, without and 
with MPs (2 × 104 MPs/μL plasma) in the presence of OHP reagent. OHP value: area under the curve 
 
36 
(absorbance vs. 2 h) of clot formation and fibrinolysis (with t-PA). Data are means ± SEM values, n = 9 
replicates. Reproduced from Paper II with permission. 
 
Consistent with the OHP assay results, in the severe HA plasma model, MPs (2 x 104 
MPs/µL plasma) improved fibrin clot structure, forming a denser fibrin network 
compared to the typical loose fibrin structure with large pores seen without MPs, 
(Figure 4.4). 
 
Figure 4.4 Standard confocal microscopy showed that MPs increased fibrin clot density in the severe 
HA plasma model. Representative images are shown of fibrin clot structures: (a), without the addition 
of MPs (MPs 0); (b) with the addition of MPs (2 × 104 MPs/μL plasma, MPs 2). Scale bar = 25 μm. 
Reproduced from Paper II with permission. 
 
To study the mechanism of this procoagulant effect, MPs were first incubated with 
lactadherin (which blocks PS on MPs), anti-TF antibodies (which blocks TF on MPs), 
or corn trypsin inhibitor (CTI, which blocks contact activation) were added to the 
plasma, before testing in the CAT and OHP assays. After targeting PS with 
lactadherin, both thrombin generation and fibrin formation were inhibited in the mild 
HA plasma model (Figure 4.5). In contrast, anti-TF antibodies did not affect the CAT 
or OHP assay results (Figure 4.5). Blocking the contact activation pathway using CTI 
slightly prolonged the lag-phase of thrombin and fibrin formation, however, the total 
thrombin generation (ETP) and fibrin formation (OHP) were not reduced (Figure 4.5).  
 
These results suggest that the mechanism by which MPs improve global hemostasis 
in HA plasma models depends mainly on the presence of PS molecules exposed on 
intact MP membranes (PS+ MPs). This is the first study to investigate the procoagulant 
effect of MPs in HA plasma models. Several studies investigated the procoagulant 
effect of MPs in normal plasma models76,104,133. Tripisciano et al. showed that platelet 
concentrate-derived MPs improved thrombin generation in normal vesicle-free plasma 
dose-dependently, which was inhibited by blocking PS but not by blocking TF133. They 
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found that the procoagulant effect of monocytic cells-derived MPs (after LPS 
stimulation) was inhibited by blocking TF133. Since we focused on MPs derived from 
human PNP, which were characterized by flow cytometry as mainly being platelet-
derived (PMPs), the contribution of TF to the procoagulant effect of MPs in our study 
was negligible.    
 
Figure 4.5 The procoagulant effect of MPs after blocking PS, TF, or contact pathway activation in the 
mild HA plasma model and the absence of CAT or OHP reagent. (a) ETP detected by the CAT assay, 
(b) OHP values detected by the OHP assay. MPs were incubated with lactadherin (MPs + lac 100 nM, 
200 nM, and 400 nM) to block PS; anti-TF antibodies (50 µg/mL) to block TF; and plasma was incubated 
with CTI before the addition of MPs (20 µg/mL) to block contact activation. Tris buffer was used as a 
negative control. Data are means ± SEM, n = 9 replicates. Reproduced from Paper II with permission. 
 
Our data showed that the procoagulant effect of MPs in HA plasma models is mostly 
independent of contact activation via FXII. Different findings have been reported in 
studies using normal plasma133-135. For example, Tripisciano et al. found that the 
addition of CTI to plasma reduced thrombin generation induced by platelet 
concentrate-derived MPs significantly, although not completely133. The inhibition of 
contact activation is more potent when CTI is directly added to the blood sampling 
tube 133-135, however, in our study, CTI was added to the HA plasma model right after 
thawing the plasma tube. It is possible that contact activation was not totally blocked 
in our study. Nevertheless, we found that blocking PS inhibited thrombin and fibrin 
formation dose-dependently, suggesting that the PS exposure on intact MP 
membranes is essential for the procoagulant effect of MPs in the HA plasma model.  
 
According to the cell-based coagulation model, the PS+ membrane is an essential 
component in the amplification and propagation phases, which provides the surface 
for the formation of coagulation complexes (including FVIIIa/FIXa and FVa/FXa), as 
shown in Figure 1.2. These two coagulation phases are impaired in HA due to the 
deficiency of FVIII. Our data in this study showed that MPs improved hemostasis in 
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HA plasma models, we suggest the underlying mechanism is that the PS+ membrane 
on MPs could accelerate the biding of FIXa and FX, and increase the formation of 
FXa, thus improve the following thrombin and fibrin formation.  
 
MPs are incorporated into the fibrin network in the HA plasma model 
Using SEM imaging, we observed “MP-like structures”, which were attached to fibrin 
fibers formed in the HA plasma model (Figure 4.6). Few attempts were made using 
immune-gold labeling SEM, however, I was not able to confirm that the particles bound 
to fibrin fibers were MPs using in vitro clots from normal plasma.  
 
 
Figure 4.6 Representative SEM image showing the “MP-like structures” (indicated by arrows) attached 
on fibrin fibers. Fibrin clots shown are from the severe HA model with the addition of PMPs (2 × 104 
PMPs/μL plasma) isolated from platelet concentrate without TRAP6 treatment. Bar = 1 μm. Reproduced 
from Paper II with permission. 
 
Confocal microscopy confirmed the platelet origin of the MPs, however, the resolution 
limit (laterally 200-300 nm) of this technique was not ideal to address the precise 
location of MPs in the fibrin network. Therefore, we used super-high-resolution STED 
imaging and showed for the first time that MPs (platelet origin) are attached to fibrin 
fibers, particularly at branch points and junctions (Figure 4.7). The specific locations 
where the MPs are incorporated into the fibrin network suggest that MPs may 
participate in the formation of fibrin monomers as well as mediate the density and 3D 





Figure 4.7 Different typical patterns showing the location of PMPs incorporated into the fibrin network 
detected by STED microscopy. (a) PMPs located at the cross point of two fibers; (b) Fiber curved 
towards the attached PMPs; (c) PMPs embedded in a mesh of fibrin fibers; (d) PMPs act as a bridge 
connecting two fibers. Images are all from the severe HA plasma model with the addition of MPs. 
Representative images from two independent experiments are shown; duplicate samples/experiment. 
Bar = 2 μm. Green: fiber (Alexa fluor 594), Red: PMPs (Aberrior STAR 635). Reproduced from Paper II 
with permission. 
 
In summary, we found that MPs improved hemostasis via the exposure of PS, and 
were incorporated at specific locations (at joints) in the growing fibrin network in in vitro 
HA plasma models, which confirmed our hypotheses of this study. Attachment of MPs 
to fibrin fibers opens opportunities to investigate the potential modulatory role of MPs 
during the fibrin formation. Our data also suggest that MPs could potentially shift the 
impaired hemostasis seen in the severe HA clinical profile, towards the moderate or 
mild HA clinical profiles. MPs might be a potential adjunctive therapy to improve 
replacement therapy in PWHA. Therefore, we continued to investigate the in vivo 
procoagulant effect of MPs in HA mice. 
 
4.2.2 MPs improve hemostasis in vivo in the HA mouse model (Paper IV) 
Based on the data from the in vitro studies, we hypothesized that treatment with MPs 
could improve hemostasis in vivo in HA mouse; and the administered MPs might be 
incorporated into the hemostatic plugs formed at the site of injury in vivo in HA mouse. 
 
40 
In addition, we hypothesized that the injected MPs might be eliminated from mice 
circulation rapidly.   
 
Administration of MPs improve hemostasis in vivo in HA mouse  
To evaluate the hemostatic effect of MPs in vivo in the HA mouse model, the 
saphenous vein bleeding model was used as described with minor modifications124. 
HA mice were treated with control saline, MPs (3.8 x 104 MPs/g mouse), rhFVIII (5 
IU/kg mouse; rFVIII-5), rhFVIII (25 IU/kg mouse; rFVIII-25) or combinations of these 
(rFVIII-5 + MPs, rFVIII-25 + MPs).  
 
Administration of 25 IU/kg rhFVIII to the HA mice revealed a similar number of 
hemostatic events as the control WT mice, and the average bleeding time was almost 
normalized (Figure 4.8), consistent with a previous study124. Treatment with MPs 
alone had little effect, and only slightly increased the number of hemostatic events and 
decreased the average bleeding time, compared to the saline-treated group of HA 
mice (Figure 4.8). Co-administration of MPs and rhFVIII did not reveal any additional 
hemostatic effect compared to treatment with rhFVIII alone (Figure 4.8). This result 
suggested that while MPs may improve hemostasis in vivo in HA mice, and their 
procoagulant effect in vivo in the HA mouse model is not potent compared to rhFVIII.  
 
Figure 4.8 Bleeding parameters of the saphenous vein bleeding model in WT mice and HA mice 
receiving different treatments. (a) the number of hemostatic events, (b) average bleeding time. n=6-9 
mice/group. Adapted from Paper IV. 
 
Results of whole blood thrombin generation assay 
Blood samples collected from mice after the bleeding model experiment (approx. 30 
min post-injection) were tested using the whole blood thrombin generation assay. HA 
mice treated with MPs prior to the saphenous vein bleeding model showed similar low 
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levels of thrombin generation compared to those treated with saline. Administration of 
rhFVIII increased thrombin generation, however, the combination of MPs and rhFVIII 
did not improve thrombin generation even further. These results suggest that no ex 
vivo improvement of thrombin generation was detected for the treatment with MPs.  
 
The contradictory findings of the in vivo and ex vivo experiments might be explained 
by the fact that the infused MPs were rapidly eliminated from mice circulation. We 
found that the injected MPs (human PNP-derived MPs) were not detectable in mice 
plasma approx. 30 min post-injection as tested using flow cytometry. Taken together, 
these results suggest that the injected MPs might be rapidly consumed by 
incorporation into the hemostatic plugs formed at the site of saphenous vein injury, or 
be rapidly eliminated from the circulation by mice organs.   
 
MPs accumulate in the thrombus formed at the site of injury in HA mice 
In order to study the incorporation of MPs at the site of injury in vivo in HA mice, we 
performed the intravital imaging of thrombus formation in the cremaster muscle of HA 
mice. Fluorescent (calcein-AM) labeled human-PNP-derived MPs were injected into 
HA mice, injury with FeCl3 was induced to the blood vessel in the cremaster muscle, 
and thrombus formation was monitored by intravital microscopy. Fluorescent signals 
corresponding to the injected MPs were detected in the thrombus formed at the site 
of injury in the HA mice (Figure 4.9). The thrombi were found to be unstable and 
washed away by blood flow, however, new thrombi were formed rapidly (within 1 
minute) again at the site of injury.  
 
Our results confirmed the hypothesis that MPs participate in the formation of thrombi 
in vivo. Furthermore, this appears to occur independently of the presence or absence 
of FVIII, as it was seen in both WT and HA mice by our group and others86,111. The 
origins of MPs used differed from our study. The first study used MPs isolated from 
blood samples from a gene-modified mouse strain (ΔCT mice111), and the second 
study used MPs from an in vitro cancer cell line (Panc02) 86. Both studies found that 
the injected MPs accumulated at the site of injury in WT mice, and the latter suggested 




Figure 4.9 Recruitment of calcein-AM-labeled MPs into the thrombus at the site of injury in HA mice 
cremaster muscle model. Composites images are shown: a merge of the FITC channel (for calcein-AM-
labeled MPs, Green) and the TRITC channel (Red). (a) image before the injury, and the rectangle 
indicate the site of injury, where a branch venule merged with a major venule (see Methods); (b) image 
after injury, the thick arrows indicate the thrombus inside the vessel, the thin arrows indicate where MPs 
were incorporated into the thrombus. Representative images are shown n=3-5 mice/group. Adapted 
from Paper IV. 
 
In the current study, we for the first time observed the incorporation of MPs in the 
thrombus formed at the injured site in vivo in HA mice. We suggest the potential 
mechanism is that MPs mimic activated platelets and bind to collagen exposed after 
injury of endothelial cells in the circulatory system and/or to fibrin via exposed 
glycoprotein IIb/IIIa135, thus participate in the formation of thrombi or hemostatic plug 
at the site of injury.  
 
Clearance of the administered MPs in mouse organs 
We showed that calcein-AM labeled MPs were endocytosed by the lung and liver but 
not the spleen of HA mice (Figure 4.10). This result partially explained our observation 
that the injected MPs were not detectable in mice circulation approx. 30 min post-
injection. Similar results were reported by one previous study, MPs were found to be 
cleared rapidly (within 5 min) by the liver and lung of WT mice in vivo89.  
 
 Fig 4.10 Clearance of MPs by the organs in 
HA mice. In HA mice injected with calcein-AM-
labeled MPs, the levels of calcein-AM+ cells in 
liver and lung were significantly higher 
compared to mice without injection of MPs. p 
values were from 4-6 separate experiments, 
based on the Mann-Whitney U test. ns, no 




In summary, data from this study confirmed our hypothesis that the administration of 
human-PNP-derived MPs could improve hemostasis in HA mice in vivo, however, this 
improvement is not as potent as the standard treatment with rhFVIII. Moreover, the 
injected MPs were partly incorporated into the thrombus formed at the site of the 
vessel injury and partly endocytosed by the liver and lung of mice rapidly. Future study 
to investigate the underlying mechanism that MPs participate in the thrombus 
formation in vivo in HA mice is of interested.   
 
Clinical perspectives of Paper II and IV 
In Paper II and IV of this thesis, I showed that human MPs (mainly platelet-derived) 
improved hemostasis both in vitro (in human plasma models of HA) and in vivo (in HA 
mice, in saphenous vein bleeding model and cremaster muscle thrombus formation 
model). I showed that MPs are incorporated into fibrin fibers and fibrin clots both in 
vitro and in vivo. The significance of my work for clinical treatment of PWHA is that it 
has generated several new hypotheses which can be tested in the future: 
1. A natural increment of MPs might be an additional bleeding modifier in some 
severe PWHA, and could transform the bleeding phenotype from a severe to a 
non-severe type, as seen in the 10–15% of “mild bleeders”, regardless of the 
FVIII concentration. MPs may be used as a potential biomarker to predict 
bleeding phenotype severity in PWHA.  
2. Theoretically, MPs could provide a potential adjunctive therapy for PWHA. The 
use of autologous MPs may shift the bleeding phenotype from severe to non-
severe, which may decrease the consumption of FVIII concentrates, and 
thereby the cost of FVIII replacement therapy.  
3. In PWHA who have increased levels of procoagulant MPs in circulation, the 
FVIII replacement therapy might need to be adjusted to reduce the potential 
risk of thrombosis, especially in middle-aged or elderly PWHA, who may have 




4.3 PREVALENCE OF CVD AND THE ROLE OF MPS IN PWHA (PAPERS III 
AND V) 
The wide availability of effective and safe FVIII concentrates has improved the life 
expectancy of PWHA significantly67. A UK study of 6018 patients (n=4874 HA and 
n=1144 HB) reported that the median survivals for patients with the severe and non-
severe disease were 63 and 75 years, respectively67. In middle-aged and elderly 
PWHA, the incidence of age-related illnesses, e.g. CVD, has become a growing 
concern55. Although PWHA seems to have a lower cardiovascular mortality67,68, they 
have at least an equal prevalence of CVD risk factors and a similar degree of 
atherosclerosis as the general control136. In Paper III of this thesis, we conducted a 
retrospective study of the prevalence of subclinical CVD in asymptomatic Swedish 
PWHA (n=29, ages 37-91 years) using the A-ECG technique. In Paper V, we 
conducted a cross-sectional study and investigated the prevalence of subclinical CVD, 
global hemostasis, and MPs profiles of Chinese PWHA treated on-demand (n= 42, 
ages 30-70 years).  
 
4.3.1 Subclinical CVD in PWHA evaluated by A-ECG (Paper III) 
We hypothesized that the CVD risk factors and subclinical CVD might be common in 
aging PWHA. ECG files of the participants were analyzed retrospectively using the A-
ECG technique in a cohort of n=29 Swedish patients. 
 
Our data showed that hypertension was modestly more prevalent in PWHA compared 
to age-matched male controls (41% vs. 21%, p=0.09). This result is consistent with 
the findings of a Sweden nation-wide study of hemophilic patients and reported that 
the prevalence of hypertension was 19.7% vs. 11.2%, in patients vs. controls137. The 
frequency of hypertension in our patient cohort was much higher compared to that of 
the national-wide study, which is probably due to our specific patient inclusion criteria 
(only those who had digital ECG file in the electronic medical record system could be 
included in our study), and these might tend to be older.  
 
Subclinical CVD risks detected by A-ECG scores 
Conventional resting ECG provides important information to diagnose several types 
of CVD, e.g. acute coronary syndromes. In the past two decades, several advanced 
(A-ECG) techniques, have been developed to detect CVD (e.g. CAD, LVH, LVSD) 
with higher sensitivity129. Using previously validated A-ECG scores, we found that 
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PWHA had a higher probability of CVD, particularly CAD/CMVD, compared to age-
matched male controls (Figure 4.11). The predicted risks of LVSH and LVH/LVER 
were also higher in PWHA vs. controls (Figure 4.11), although risks for these diseases 
were much lower than that of CAD/CMVD.  
 
Figure 4.11 Subclinical CVD in PWHA and controls evaluated using A-ECG. Validated A-ECG scores 
were used to determine the probability of having CVD, LVSD, and CAD/CMVD, as well as the 
prevalence of LVH/LVER. Reproduced from Paper III with permission. 
 
These results suggest that subclinical CVD is common in asymptomatic PWHA, who 
have access to adequate replacement therapy. Therefore, it is important to monitor 
the development of CVD in PWHA ≥40 years old. Furthermore, this study indicates 
that the A-ECG technique may be useful in detecting early CVD changes in PWHA.    
 
4.3.2 Subclinical CVD and the role of MPs in PWHA treated on-demand 
(Paper V) 
PWHA have lower cardiovascular mortality due to their hypocoagulable state69. 
However, this protective effect might be reduced by regular prophylaxis with FVIII 
concentrates. To better understand the protective effect of FVIII deficiency on the 
development of CVD, we investigated the prevalence of CVD risk factors and 
subclinical CVD in Chinese PWHA treated on-demand (n=42, ages 30-70 years). We 
also evaluated in these patients their MPs profiles by flow cytometry and correlated 
these with their risk of CVD.  
 
We hypothesized that PWHA treated on-demand might have a reduced risk of CVD 
(cardiac disease) compared to normal individuals due to their hypocoagulation status, 




Clinical characteristics of PWHA treated on-demand As expected, PWHA treated 
on-demand, especially those with severe HA, had frequent spontaneous bleeding and 
insufficient treatment, which led to a relatively high prevalence of hemophilic 
arthropathy (Table 4.1).  
 
We found that the prevalence of hypertension in this group of PWHA tended to be 
higher compared to the age-matched male control group (19% vs. 14.8%, p= 0.651). 
The other CVD risk factors were also relatively common in PWHA treated on-demand.  
 
Table 4.1. Clinical characteristics of PWHA treated on-demand. Adapted from Paper V. 






Age (years, mean ± SD) 42.3 ± 10.7  38.8 ± 8.6 46.9 ± 11.6 
Frequency of spontaneous bleeding     
    No 7 (16.7%) 0 7 (38.9%) 
    1-3 times/year 9 (21.4%) 4 (16.7%) 5 (27.8%) 
    3-10 times/year 6 (14.3%) 4 (16.7%) 2 (11.1%) 
>10 times/year 20 (47.6%) 16 (66.7%) 4 (22.2%) 
Frequency of the replacement therapy    
    No 2 (4.8%) 0 2 (11.1%) 
    1-3 times/year 9 (21.4%) 3 (12.5%) 6 (33.3%) 
    3-10 times/year 8 (19%) 7 (29.2%) 1 (5.6%) 
>10 times/year 23 (54.8%) 14 (58.3%) 9 (50.0%) 
chronic arthropathy with limited joint 
movement  
   
    No 6 (14.3%) 1 (4.2%) 5 (27.8%) 
    Yes 36 (85.7%) 23 (95.8%) 13 (72.2%) 
 
Subclinical CVD risks in PWHA treated on-demand 
Our data showed that PWHA had a similar probability of developing CVD as the age-
matched male controls (median [interquartile range] 27.04 [4.87-92.61]% vs. 22.89 
[1.63-43.06]%, p=0.204, Figure 4.12), which did not confirm our hypothesis. 
Compared to the patients with non-severe HA, patients with severe HA trended 
towards a lower predicted CVD risk (20.58 [3.58-86.16]% vs. 38.80 [5.92-96.58]%, 
p=0.294, Figure 4.12). This result suggests that PWHA treated on-demand are not 
protected from developing subclinical CVD due to their hypocoagulation status caused 




Figure 4.12 Probability of having CVD as evaluated using the A-ECG technique in PWHA and controls. 
Controls, n=21; and patients with HA, n=37 (21 have severe and 16 have non-severe HA). ns, no 
significant difference compared to the control group. Adapted from Paper V. 
 
In the Chinese study, the predicted CVD risk of PWHA treated only on-demand was 
much lower than that in the Swedish study of PWHA treated prophylactically (as 
described in the Results of Paper III). This might due to the difference in the age of 
patients included in the two studies, since the Chinese cohort is younger than the 
Swedish cohort, their CVD risks are expected to be lower. The difference between the 
A-ECG scores used in the two studies should also be noted. In both studies, the A-
ECG scores involved both conventional ECG parameters, as well as A-ECG 
parameters (i.e. the derived vector cardiographic ECG parameters and QRS and T 
waveform complexity measures). However, in the Chinese study (Paper V), A-ECG 
parameters for the beat-to-beat variability of the R-to-R and QT intervals were also 
included in the A-ECG analysis, because a 5-min ECG file was collected from each 
participant.  
 
Swedish PWHA have access to adequate treatment, and prophylaxis is the standard 
treatment for patients with FVIII levels below 1-2%137. We assume that patients with 
prophylaxis may have higher risks of developing CVD compared to those with on-
demand therapy. To test this hypothesis, a further study designed to compare the 
prevalence of subclinical CVD in age-matched patients with different treatment 
regimens (prophylaxis vs. on-demand) would be of interest.  
 
MPs profiles in Chinese PWHA treated on-demand vs. normal controls 
PWHA had significantly higher levels of PMPs (656.5 [472.0 - 826.8] vs. 494.0 [310.0 
– 823.5], p=0.047) and CD62+ MPs (136.5 [117.8 – 164.8 vs. 107.0 [93.0 – 128.5], 
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p<0.001] compared to the normal controls (Figure 4.13). This result suggests a higher 
level of platelet activation in the PWHA compared to controls. One earlier study 
reported increase CD62P exposure in platelets of PWHA at baseline and suggested 
that platelets are pre-activated in PWHA28. The level of baseline activated platelets, 
however, did not correlate with the clinical bleeding severity29. No differences were 
found in the levels of different types of MPs among patients with severe vs. non-severe 
HA (Figure 4.13). Interestingly, higher counts of CD62P+ MPs were correlated with 
reduced capacity for fibrin clot formation, suggesting that impaired coagulation may 
be the reason for the increased platelet activation in PWHA. 
 
Figure 4.13 MPs profiles in PWHA and age-matched male controls. The graphs show the level of PMPs 
and P-selectin (CD62P+) MPs as measured by flow cytometry in the controls (n=37) and PWHA (n=42, 
with 24 have severe and 18 have non-severe HA). ns, no significant difference as compared to the 
control group. Adapted from Paper V. 
 
Correlations between MPs levels and CVD risks 
Several studies have reported elevated MPs, particularly EMPs in patients with 
CVD138. EMPs are released from endothelial cells upon activation and apoptosis. 
EMPs serve as a biomarker for endothelial dysfunction, which could lead to the 
development of CVD113. In the current study, we did not find any correlation between 
the MPs profiles (level of different types of MPs) and the risk of subclinical CVD, as 
evaluated by flow cytometry and A-ECG (Table 4.2).  
 
Increased endothelial cell dysfunction has been reported in PWHA in other clinical 
studies, including increased levels of soluble intercellular adhesion molecule-1 and 
interleukin-6 in serum139, and impaired flow-mediated dilation measured by 
ultrasound64. These results suggest that other molecules in PWHA might be more 
sensitive biomarkers for the detection of impaired endothelial cell function compared 
to the level of EMPs.  
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Table 4.2 Analysis showing no significant correlations between CVD risk, and MPs profiles in the 
Chinese study PWHA treated on-demand. Adapted from Paper V. 
Subtype of MPs The probability of having cardiac 
disease, p (r) 
PS+ MPs 0.503 (0.090) 
PMP+ 0.742 (0.044) 
EMP+ 0.473 (0.096) 
LMP+ 0.599 (0.071) 
TF+ MPs 0.693 (-0.053) 
CD62P+ 0.280 (0.144) 
                          r, Spearman’s correlation coefficient. 
 
In summary, our results show that PWHA (≥30 years old) treated on-demand are not 
protected from developing subclinical CVD, thus our hypothesis that PWHA treated 
on-demand have lower CVD risk is not confirmed by this study. Moreover, no 
correlations between CVD risks and MPs profiles were found. Interestingly, the 
increased levels of PMPs and CD62+ MPs correlated with the impaired fibrin formation 
in PWHA, suggesting that the hypocoagulable state in PWHA might result in increased 
platelet activation.  
 
Clinical perspectives of Paper III and V 
In Paper III and V of this thesis, I showed that subclinical CVD risks are at least equally 
common (Paper V) or even more prevalent (Paper III) among PWHA ≥30 years old as 
compared to age-matched male controls. Therefore, the presence of CVD risk factors, 
as well as subclinical CVD, should be monitored in those patients. A-ECG as a rapid, 
convenient, and accurate method, could be used to detect CVD in PWHA, even when 
no overt clinical indications of CVD are present.   
 
Although we did not find any correlation between the MPs profiles and CVD risks 
predicted by A-ECG, we assume the level of MPs might be a potential biomarker for 
the risk of atherothrombosis in aging PWHA. Elevated levels of PMPs and CD62+ 
MPs were found in PWHA. Based on our in vitro and in vivo results in Paper II and IV, 
we hypothesize that these subtypes of MPs may participate in the thrombus formation 
at the site of injured endothelial cells, by mimicking the role of platelets in hemostasis 




Since middle-aged and elderly PWHA generally have few physical activities compared 
to younger patients, and their CVD risks, especially risks of hypertension, are 
increased, adjustment for the FVIII replacement therapy (decrease dose and/or 
frequency) might be beneficial. Further studies to investigate MPs as a biomarker to 





The key findings of the studies included in this thesis can be summarized as below: 
 
1. Paper I: 
SIA in combination with high concentrations of aPCC induces hypercoagulable 
changes in fibrin clot formation and structure in in vitro HA plasma model, suggesting 
that this combination might be prothrombotic when used in the clinics to treat PWHA.  
 
2. Paper II and IV: 
MPs partially restore hemostasis in HA and are incorporated into the fibrin network of 
HA, both in vitro and in vivo.  
 
3. Paper III and V: 
In Paper III, we show that in the Swedish PWHA ≥40 years old, A-ECG exhibits 
increased risk of subclinical CVD compared to the age-matched male controls.   
In Paper V, we demonstrate that the Chinese PWHA treated on-demand ≥30 years 
old are not protected from developing subclinical CVD, and the hypercoagulable state 
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